Clinical Survey Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III)

Trial Information
Status: Active, not recruiting
Location: See all (4) locations...
Intervention Type: Other
Study Type: Observational
Summary

The primary objective of this study is to evaluate potential biomarkers of GSD III.

Am I eligible for this trial?
Participation Requirements
Sex:
All
Minimum Age:
5
Maximum Age:
65
Healthy Volunteers:
No

• Confirmed historical diagnosis of GSD III based on pathogenic mutations in the AGL gene on both alleles or GDE deficiency based on biopsy of liver, muscle, or fibroblasts

• Willing to comply with all study procedures

• Willing and able to provide written informed consent. If a minor, willing and able to provide written assent and have a legally authorized representative willing and able to provide written informed consent

Where is this trial taking place?
United States
California
University of California
Irvine
Children's Hospital Orange County
Orange
Colorado
Colorado Children's Hospital
Aurora
Texas
University of Texas Medical School
Houston
When is this trial taking place?
Start Date: November 23, 2020
Estimated Completion Date: July 2022
How many participants will be in this trial?
Target number of participants: 18
What other conditions are being studied in this trial?

This content was sourced from clinicaltrials.gov

Phase III Clinical Trial of Purified Inactivated Japanese Encephalitis Vaccine
Who is this study for:Patients with Japanese Encephalitis Virus Disease
Status:Active, not recruiting
Start Date:September 1, 2015
Study Drug:Japanese Encephalitis Vaccine produced by IMBCAMS
Study Type:Biological
Phase: Phase 3